Literature DB >> 30014619

Transcriptome-Wide Analysis Reveals the Landscape of Aberrant Alternative Splicing Events in Liver Cancer.

Shengli Li1, Zhixiang Hu1, Yingjun Zhao1, Shenglin Huang1, Xianghuo He1,2.   

Abstract

Alternative splicing (AS) is assumed to be a pivotal determinant for the generation of diverse transcriptional variants in cancer. However, the comprehensive dysregulation of AS and the prospective biological and clinical relevance in hepatocellular carcinoma (HCC) remain obscure. Here, we identified and depicted the AS landscape in HCC by performing reference-based assembly of sequencing reads from over 600 RNA sequencing (RNA-seq) libraries. We detected various differentially spliced ASEs across patients covering not only protein-coding genes, but also considerable numbers of noncoding genes. Strikingly, alternative transcription initiation was found to frequently occur in HCC. These differential ASEs were highly related to "cancer hallmarks" and involved in metabolism-related pathways in particular. In addition, 243 differential ASEs were identified as risk predictors for HCC patient survival. The isoform switch of metabolism-related gene UGP2 (UDP-glucose pyrophosphorylase 2) might play an essential role in HCC. We further constructed regulatory networks between RNA-binding protein (RBP) genes and the corresponding ASEs. Further analysis demonstrated that the regulated networks were enriched in a variety of metabolism-related pathways.
Conclusion: Differential ASEs are prevalent in HCC, where alternative transcription initiation was found to frequently occur. We found that genes having differential ASEs were significantly enriched in metabolism-related pathways. The expression variations, binding relations, and even mutations of RBP genes largely influenced differential ASEs in HCC.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2018        PMID: 30014619     DOI: 10.1002/hep.30158

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

Review 1.  Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability.

Authors:  Maddalen Jimenez; María Arechederra; Matías A Ávila; Carmen Berasain
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-31

2.  RNA processing genes characterize RNA splicing and further stratify lower-grade glioma.

Authors:  Rui-Chao Chai; Yi-Ming Li; Ke-Nan Zhang; Yu-Zhou Chang; Yu-Qing Liu; Zheng Zhao; Zhi-Liang Wang; Yuan-Hao Chang; Guan-Zhang Li; Kuan-Yu Wang; Fan Wu; Yong-Zhi Wang
Journal:  JCI Insight       Date:  2019-08-13

3.  Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma.

Authors:  Youli Du; Xiaoou Ma; Dongxu Wang; Yuguang Wang; Tianyu Zhang; Lianjie Bai; Yunlong Liu; Shaosen Chen
Journal:  J Gastrointest Oncol       Date:  2021-10

4.  SNRPC promotes hepatocellular carcinoma cell motility by inducing epithelial-mesenchymal transition.

Authors:  Yuanping Zhang; Jiliang Qiu; Dinglan Zuo; Yichuan Yuan; Yuxiong Qiu; Liang Qiao; Wei He; Binkui Li; Yunfei Yuan
Journal:  FEBS Open Bio       Date:  2021-05-12       Impact factor: 2.693

5.  The landscape and biological relevance of aberrant alternative splicing events in esophageal squamous cell carcinoma.

Authors:  Quanyou Wu; Yuan Zhang; Haiyin An; Wei Sun; Ruozheng Wang; Meng Liu; Kaitai Zhang
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

6.  Integrated Characterization of lncRNA-Immune Interactions in Prostate Cancer.

Authors:  Wei Hu; Yanru Wang; Zhixiao Fang; Wei He; Shengli Li
Journal:  Front Cell Dev Biol       Date:  2021-02-16

7.  Integrated Analysis of the Prognosis-Associated RNA-Binding Protein Genes and Candidate Drugs in Renal Papillary Cell Carcinoma.

Authors:  Silin Jiang; Xiaohan Ren; Shouyong Liu; Zhongwen Lu; Aiming Xu; Chao Qin; Zengjun Wang
Journal:  Front Genet       Date:  2021-02-12       Impact factor: 4.599

8.  SUVA: splicing site usage variation analysis from RNA-seq data reveals highly conserved complex splicing biomarkers in liver cancer.

Authors:  Chao Cheng; Lei Liu; Yongli Bao; Jingwen Yi; Weili Quan; Yaqiang Xue; Luguo Sun; Yi Zhang
Journal:  RNA Biol       Date:  2021-06-21       Impact factor: 4.766

9.  Systematic Profiling of Alternative Splicing for Sarcoma Patients Reveals Novel Prognostic Biomarkers Associated with Tumor Microenvironment and Immune Cells.

Authors:  Chuan Hu; Yuanhe Wang; Chuan Liu; Rui Shen; Bo Chen; Kang Sun; Huili Rao; Lin Ye; Jianjun Ye; Shaoqi Tian
Journal:  Med Sci Monit       Date:  2020-07-19

10.  LINC01348 suppresses hepatocellular carcinoma metastasis through inhibition of SF3B3-mediated EZH2 pre-mRNA splicing.

Authors:  Yang-Hsiang Lin; Meng-Han Wu; Yi-Chung Liu; Ping-Chiang Lyu; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Oncogene       Date:  2021-06-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.